Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer

Retrieve available abstracts of 153 articles:
HTML format



Single Articles


    October 2021
  1. OZAKI A, Tachibana K, Ohtake T
    Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Toho
    Breast Cancer. 2021 Oct 13. pii: 10.1007/s12282-021-01306.
    PubMed    


  2. LI B, Cheng X, Zhu Y, Wan H, et al
    FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population.
    Breast Cancer. 2021 Oct 11. pii: 10.1007/s12282-021-01305.
    PubMed     Abstract available


  3. LEBOK P, Bonte H, Kluth M, Moller-Koop C, et al
    6q deletion is frequent but unrelated to patient prognosis in breast cancer.
    Breast Cancer. 2021 Oct 8. pii: 10.1007/s12282-021-01301.
    PubMed     Abstract available


  4. HORISAWA N, Adachi Y, Takatsuka D, Nozawa K, et al
    The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
    Breast Cancer. 2021 Oct 7. pii: 10.1007/s12282-021-01303.
    PubMed     Abstract available


    September 2021
  5. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Breast Cancer. 2021 Sep 30. pii: 10.1007/s12282-021-01300.
    PubMed     Abstract available


  6. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01296.
    PubMed    


  7. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analys
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01299.
    PubMed    


  8. KAMIYA S, Satake H, Hayashi Y, Ishigaki S, et al
    Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
    Breast Cancer. 2021 Sep 16. pii: 10.1007/s12282-021-01294.
    PubMed     Abstract available


  9. XU J, Iwabuchi E, Miki Y, Kanai A, et al
    FE65 in breast cancer and its clinicopathological significance.
    Breast Cancer. 2021 Sep 8. pii: 10.1007/s12282-021-01291.
    PubMed     Abstract available


  10. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 7. pii: 10.1007/s12282-021-01290.
    PubMed     Abstract available


  11. TOKUNAGA E, Masuda T, Ijichi H, Tajiri W, et al
    Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer. 2021 Sep 6. pii: 10.1007/s12282-021-01292.
    PubMed     Abstract available


    August 2021
  12. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the globa
    Breast Cancer. 2021 Aug 31. pii: 10.1007/s12282-021-01283.
    PubMed     Abstract available


  13. LAI J, Chen B, Li Y, Lin X, et al
    Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
    Breast Cancer. 2021 Aug 27. pii: 10.1007/s12282-021-01289.
    PubMed     Abstract available


  14. BRANDS-APPELDOORN ATPM, Maaskant-Braat AJG, Janssen L, van Osch LADM, et al
    Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy.
    Breast Cancer. 2021 Aug 26. pii: 10.1007/s12282-021-01287.
    PubMed     Abstract available


  15. SUZUKI Y, Wenwen W, Ohta T, Hayashi SI, et al
    Correction to: Molecular targeted drugs resistance impairs doublestrand break repair and sensitizes ERpositive breast cancer to PARP inhibitors.
    Breast Cancer. 2021 Aug 22. pii: 10.1007/s12282-021-01288.
    PubMed    


  16. ZHU L, Pan JN, Qian Z, Ye WW, et al
    High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
    Breast Cancer. 2021 Aug 17. pii: 10.1007/s12282-021-01286.
    PubMed     Abstract available


  17. HAMADNEH L, Bahader M, Abuarqoub R, AlWahsh M, et al
    PI3K/AKT and MAPK1 molecular changes preceding matrix metallopeptidases overexpression during tamoxifen-resistance development are correlated to poor prognosis in breast cancer patients.
    Breast Cancer. 2021 Aug 9. pii: 10.1007/s12282-021-01277.
    PubMed     Abstract available


  18. LEE DG, Schuetz JM, Lai AS, Burstyn I, et al
    Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer.
    Breast Cancer. 2021 Aug 5. pii: 10.1007/s12282-021-01279.
    PubMed     Abstract available


  19. HUANG SL, Huang ZC, Zhang CJ, Xie J, et al
    LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299.
    Breast Cancer. 2021 Aug 5. pii: 10.1007/s12282-021-01281.
    PubMed     Abstract available


  20. SUZUKI Y, Wenwen W, Ohta T, Hayashi SI, et al
    Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    Breast Cancer. 2021 Aug 3. pii: 10.1007/s12282-021-01282.
    PubMed     Abstract available


  21. ZARIFMAHMOUDI L, Aghaee A, Treglia G, Sadeghi R, et al
    Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of cN0 and cN + patients.
    Breast Cancer. 2021 Aug 2. pii: 10.1007/s12282-021-01280.
    PubMed     Abstract available


    July 2021
  22. QIAO Y, van Londen GJ, Brufsky JW, Poppenberg JT, et al
    Perceived physical fatigability improves after an exercise intervention among breast cancer survivors: a randomized clinical trial.
    Breast Cancer. 2021 Jul 30. pii: 10.1007/s12282-021-01278.
    PubMed     Abstract available


  23. TAKAHASHI S, Fukui T, Nomizu T, Kakugawa Y, et al
    TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients.
    Breast Cancer. 2021 Jul 24. pii: 10.1007/s12282-021-01250.
    PubMed     Abstract available


  24. UEMOTO Y, Uchida M, Kondo N, Wanifuchi-Endo Y, et al
    Predictive factors for patients who need treatment for chronic post-surgical pain (CPSP) after breast cancer surgery.
    Breast Cancer. 2021 Jul 22. pii: 10.1007/s12282-021-01275.
    PubMed     Abstract available


  25. GASTERATOS K, Morsi-Yeroyannis A, Vlachopoulos NC, Spyropoulou GA, et al
    Microsurgical techniques in the treatment of breast cancer-related lymphedema: a systematic review of efficacy and patient outcomes.
    Breast Cancer. 2021 Jul 12. pii: 10.1007/s12282-021-01274.
    PubMed     Abstract available


  26. SANGHA MS, Baker R, Ahmed M
    Axillary dissection versus axillary observation for low risk, clinically node-negative invasive breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2021 Jul 9. pii: 10.1007/s12282-021-01273.
    PubMed     Abstract available


  27. TOYODA Y, Katanoda K, Ishii K, Yamamoto H, et al
    Negative impact of the COVID-19 state of emergency on breast cancer screening participation in Japan.
    Breast Cancer. 2021 Jul 9. pii: 10.1007/s12282-021-01272.
    PubMed     Abstract available


  28. GIORELLO MB, Matas A, Marenco P, Davies KM, et al
    CD1a- and CD83-positive dendritic cells as prognostic markers of metastasis development in early breast cancer patients.
    Breast Cancer. 2021 Jul 9. pii: 10.1007/s12282-021-01270.
    PubMed     Abstract available


  29. PHAM TM, Nguyen DK, Pham HM, Le DC, et al
    Average lifespan shortened due to breast cancer in Australia, 1990-2015.
    Breast Cancer. 2021 Jul 8. pii: 10.1007/s12282-021-01271.
    PubMed     Abstract available


    June 2021
  30. AMIOKA A, Kadoya T, Sueoka S, Kobayashi Y, et al
    Correction to: Effect of Wnt5a on drug resistance in estrogen receptorpositive breast cancer.
    Breast Cancer. 2021 Jun 28. pii: 10.1007/s12282-021-01268.
    PubMed    


  31. PARKS RM, Alfarsi LH, Green AR, Cheung KL, et al
    Biology of primary breast cancer in older women beyond routine biomarkers.
    Breast Cancer. 2021 Jun 24. pii: 10.1007/s12282-021-01266.
    PubMed     Abstract available


  32. JOSHI A, Larkins S, Evans R, Moodley N, et al
    Use and impact of breast cancer survivorship care plans: a systematic review.
    Breast Cancer. 2021 Jun 19. pii: 10.1007/s12282-021-01267.
    PubMed     Abstract available


  33. GHOREISHY SM, Aminianfar A, Benisi-Kohansal S, Azadbakht L, et al
    Association between dietary phytochemical index and breast cancer: a case-control study.
    Breast Cancer. 2021 Jun 13. pii: 10.1007/s12282-021-01265.
    PubMed     Abstract available


  34. LIN Y, Xu Y, Wang C, Song Y, et al
    Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis.
    Breast Cancer. 2021 Jun 9. pii: 10.1007/s12282-021-01263.
    PubMed     Abstract available


    May 2021
  35. AMIOKA A, Kadoya T, Sueoka S, Kobayashi Y, et al
    Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
    Breast Cancer. 2021 May 28. pii: 10.1007/s12282-021-01241.
    PubMed     Abstract available


  36. INOKUCHI M, Kutomi G, Kijima Y, Sakai T, et al
    Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01256.
    PubMed    


  37. YAMAUCHI C, Yoshimura M, Sekiguchi K, Hamamoto Y, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01255.
    PubMed    


  38. IWATA H, Saji S, Ikeda M, Inokuchi M, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01253.
    PubMed    


  39. UEMATSU T, Nakashima K, Kikuchi M, Kubota K, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01251.
    PubMed    


  40. WANG L, Li Q, Aushev VN, Neugut AI, et al
    PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Breast Cancer. 2021 May 18. pii: 10.1007/s12282-021-01261.
    PubMed     Abstract available


  41. PEARSON A, Dhillon HM, Kiely BE
    Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?
    Breast Cancer. 2021 May 11. pii: 10.1007/s12282-021-01260.
    PubMed     Abstract available


  42. CHEN XQ, Zhang F, Xiao FH, Peng Y, et al
    Deciphering the nexus between the tumor immune microenvironment and DNA methylation in subgrouping estrogen receptor-positive breast cancer.
    Breast Cancer. 2021 May 8. pii: 10.1007/s12282-021-01262.
    PubMed     Abstract available


  43. CHAO X, Tan W, Tsang JY, Tse GM, et al
    Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases.
    Breast Cancer. 2021 May 3. pii: 10.1007/s12282-021-01246.
    PubMed     Abstract available


  44. VILLASCO A, Accomasso F, D'Alonzo M, Agnelli F, et al
    Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
    Breast Cancer. 2021 May 3. pii: 10.1007/s12282-021-01258.
    PubMed     Abstract available


    April 2021
  45. HIRATA K, Narabayashi M, Hanai Y, Fukumoto K, et al
    Comparison of thoracic and abdominal deep inspiration breath holds in whole-breast irradiation for patients with left-sided breast cancer.
    Breast Cancer. 2021 Apr 28. pii: 10.1007/s12282-021-01259.
    PubMed     Abstract available


  46. SHIMOI T, Nagai SE, Yoshinami T, Takahashi M, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
    Breast Cancer. 2021 Apr 22. pii: 10.1007/s12282-021-01252.
    PubMed    


  47. ADACHI Y, Oze I, Sawaki M, Hattori M, et al
    Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
    Breast Cancer. 2021 Apr 22. pii: 10.1007/s12282-021-01245.
    PubMed     Abstract available


  48. OZAKI A, Tachibana K, Ohtake T
    Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Ja
    Breast Cancer. 2021 Apr 20. pii: 10.1007/s12282-021-01254.
    PubMed    


  49. NAGASAKI E, Kudo R, Tamura M, Hayashi K, et al
    Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
    Breast Cancer. 2021 Apr 11. pii: 10.1007/s12282-021-01240.
    PubMed     Abstract available


  50. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Comparisons of postoperative outcomes after breast cancer surgery in patients with and without renal replacement therapy: a matched-pair cohort study using a Japanese nationwide inpatient database.
    Breast Cancer. 2021 Apr 10. pii: 10.1007/s12282-021-01248.
    PubMed     Abstract available


  51. PAPPOT H, Baeksted CW, Nissen A, Knoop A, et al
    Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study.
    Breast Cancer. 2021 Apr 9. pii: 10.1007/s12282-021-01244.
    PubMed     Abstract available


  52. ZHANG J, Tian Q, Zhang M, Wang H, et al
    Immune-related biomarkers in triple-negative breast cancer.
    Breast Cancer. 2021 Apr 9. pii: 10.1007/s12282-021-01247.
    PubMed     Abstract available


  53. SONG C, Lowe VJ, Lee S
    Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC).
    Breast Cancer. 2021 Apr 3. pii: 10.1007/s12282-021-01242.
    PubMed     Abstract available


  54. FUTAMURA M, Oba M, Masuda N, Bando H, et al
    Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Breast Cancer. 2021 Apr 3. pii: 10.1007/s12282-021-01238.
    PubMed     Abstract available


  55. TAKADA M, Tanaka G, Hashimoto H, Hirai Y, et al
    Practical approach to prevent COVID-19 infection at breast cancer screening.
    Breast Cancer. 2021 Apr 2. pii: 10.1007/s12282-021-01235.
    PubMed     Abstract available


  56. INOUE K, Masuda N, Iwata H, Takahashi M, et al
    Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Breast Cancer. 2021 Apr 1. pii: 10.1007/s12282-021-01239.
    PubMed     Abstract available


    March 2021
  57. NAHVIJOU A, Safari H, Ameri H
    Correction to: Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Breast Cancer. 2021 Mar 26. pii: 10.1007/s12282-021-01243.
    PubMed    


  58. DU L, Tao X, Shen X
    Human umbilical cord mesenchymal stem cell-derived exosomes inhibit migration and invasion of breast cancer cells via miR-21-5p/ZNF367 pathway.
    Breast Cancer. 2021 Mar 26. pii: 10.1007/s12282-021-01218.
    PubMed     Abstract available


  59. SASADA S, Masumoto N, Emi A, Kadoya T, et al
    Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis.
    Breast Cancer. 2021 Mar 19. pii: 10.1007/s12282-021-01236.
    PubMed     Abstract available


  60. BARZGAR BAROUGH N, Sajjadian F, Jalilzadeh N, Shafaei H, et al
    Understanding breast cancer heterogeneity through non-genetic heterogeneity.
    Breast Cancer. 2021 Mar 15. pii: 10.1007/s12282-021-01237.
    PubMed     Abstract available


  61. VINH-HUNG V, Everaert H, Gorobets O, Van Parijs H, et al
    Breast cancer preoperative (18)FDG-PET, overall survival prognostic separation compared with the lymph node ratio.
    Breast Cancer. 2021 Mar 10. pii: 10.1007/s12282-021-01234.
    PubMed     Abstract available


  62. WANG LF, Eaglehouse YL, Poppenberg JT, Brufsky JW, et al
    Effects of a personal trainer-led exercise intervention on physical activity, physical function, and quality of life of breast cancer survivors.
    Breast Cancer. 2021 Mar 10. pii: 10.1007/s12282-020-01211.
    PubMed     Abstract available


  63. TAN PY, Teng KT
    Role of dietary fat on obesity-related postmenopausal breast cancer: insights from mouse models and methodological considerations.
    Breast Cancer. 2021 Mar 9. pii: 10.1007/s12282-021-01233.
    PubMed     Abstract available


  64. TAKAHASHI M, Inoue K, Mukai H, Yamanaka T, et al
    Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Breast Cancer. 2021 Mar 7. pii: 10.1007/s12282-021-01232.
    PubMed     Abstract available


  65. NAHVIJOU A, Safari H, Ameri H
    Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Breast Cancer. 2021 Mar 5. pii: 10.1007/s12282-021-01230.
    PubMed     Abstract available


  66. MCMULLEN ER, Skala SL, Gonzalez ME, Djomehri S, et al
    Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
    Breast Cancer. 2021;28:496-505.
    PubMed     Abstract available


  67. MAEDA H, Hayashida T, Watanuki R, Kikuchi M, et al
    Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US).
    Breast Cancer. 2021;28:398-404.
    PubMed     Abstract available


  68. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
    Gene expression profile of normal breast tissue and body mass index.
    Breast Cancer. 2021;28:488-495.
    PubMed     Abstract available


  69. FILIPE MD, Simons JM, Moeliker L, Waaijer L, et al
    Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge.
    Breast Cancer. 2021;28:471-477.
    PubMed     Abstract available


  70. VERDE F, Vigliar E, Romeo V, Campanino MR, et al
    Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): a challenging cytological diagnosis with hybrid PET/MRI staging and follow-up.
    Breast Cancer. 2021;28:527-532.
    PubMed     Abstract available


  71. KUMARI K, Kumar S, Parida DK, Mishra SK, et al
    EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.
    Breast Cancer. 2021;28:355-367.
    PubMed     Abstract available


  72. GLASGOW A, Sechrist H, Bomeisl P, Gilmore H, et al
    Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Breast Cancer. 2021;28:321-328.
    PubMed     Abstract available


  73. CARRARA GFA, Evangelista AF, Scapulatempo-Neto C, Abrahao-Machado LF, et al
    Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival.
    Breast Cancer. 2021;28:307-320.
    PubMed     Abstract available


  74. ZHAO JM, An Q, Sun CN, Li YB, et al
    Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Breast Cancer. 2021;28:298-306.
    PubMed     Abstract available


  75. VUKSANOVIC D, Sanmugarajah J, Lunn D, Sawhney R, et al
    Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.
    Breast Cancer. 2021;28:289-297.
    PubMed     Abstract available


  76. ALATAWI Y, Hansen RA, Chou C, Qian J, et al
    The impact of cognitive impairment on survival and medication adherence among older women with breast cancer.
    Breast Cancer. 2021;28:277-288.
    PubMed     Abstract available


    February 2021
  77. KUREBAYASHI J, Shiba E, Toyama T, Matsumoto H, et al
    A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-respons
    Breast Cancer. 2021 Feb 27. pii: 10.1007/s12282-020-01205.
    PubMed     Abstract available


  78. KURODA H, Jamiyan T, Yamaguchi R, Kakumoto A, et al
    Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.
    Breast Cancer. 2021 Feb 25. pii: 10.1007/s12282-021-01227.
    PubMed     Abstract available


  79. KAWATE T, Yoshida A, Sugae S, Asaga S, et al
    Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society.
    Breast Cancer. 2021 Feb 20. pii: 10.1007/s12282-020-01214.
    PubMed     Abstract available


  80. OHARA A, Naoi Y, Shimoda M, Tanei T, et al
    Impact of tumor cellularity on the HER2 amplification assay by OncoScan in breast cancer.
    Breast Cancer. 2021 Feb 16. pii: 10.1007/s12282-021-01226.
    PubMed     Abstract available


  81. PARK S, Jeong J, Han W, Lee YJ, et al
    Is mastectomy with immediate reconstruction safe for patients undergoing neoadjuvant chemotherapy? A nationwide study from Korean Breast Cancer Society.
    Breast Cancer. 2021 Feb 14. pii: 10.1007/s12282-021-01223.
    PubMed     Abstract available


  82. ZHANG Y, Tian J, Qu C, Peng Y, et al
    Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
    Breast Cancer. 2021 Feb 10. pii: 10.1007/s12282-021-01221.
    PubMed     Abstract available


  83. OCHI T, Tsunoda H, Matsuda N, Nozaki F, et al
    Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Breast Cancer. 2021 Feb 9. pii: 10.1007/s12282-021-01220.
    PubMed     Abstract available


  84. QUI S, Takeshita T, Sueta A, Tomiguchi M, et al
    Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum.
    Breast Cancer. 2021 Feb 4. pii: 10.1007/s12282-020-01212.
    PubMed     Abstract available


    January 2021
  85. TANAKA Y, Ohno T, Kadonaga T, Kidokoro Y, et al
    Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype.
    Breast Cancer. 2021 Jan 22. pii: 10.1007/s12282-021-01217.
    PubMed     Abstract available


  86. OHNUKI K, Tohno E, Tsunoda H, Uematsu T, et al
    Correction to: Overall assessment system of combined mammography and ultrasound for breast cancer screening in Japan.
    Breast Cancer. 2021 Jan 21. pii: 10.1007/s12282-021-01216.
    PubMed    


  87. LIU X, Chang Q, Wang H, Qian H, et al
    Discovery and function exploration of microRNA-155 as a molecular biomarker for early detection of breast cancer.
    Breast Cancer. 2021 Jan 21. pii: 10.1007/s12282-021-01215.
    PubMed     Abstract available


  88. SONG BI
    A machine learning-based radiomics model for the prediction of axillary lymph-node metastasis in breast cancer.
    Breast Cancer. 2021 Jan 17. pii: 10.1007/s12282-020-01202.
    PubMed     Abstract available


  89. CHEN Y, Noma S, Taguchi Y, Takahashi M, et al
    Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
    Breast Cancer. 2021 Jan 16. pii: 10.1007/s12282-020-01207.
    PubMed     Abstract available


  90. HSUEH EJ, Loh EW, Lin JJ, Tam KW, et al
    Effects of yoga on improving quality of life in patients with breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer. 2021 Jan 15. pii: 10.1007/s12282-020-01209.
    PubMed     Abstract available


  91. SHIRDARREH M, Pezo RC
    Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review.
    Breast Cancer. 2021 Jan 11. pii: 10.1007/s12282-020-01213.
    PubMed     Abstract available


  92. NEDELJKOVIC M, Tanic N, Prvanovic M, Milovanovic Z, et al
    Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
    Breast Cancer. 2021 Jan 8. pii: 10.1007/s12282-020-01210.
    PubMed     Abstract available


  93. CAO W, Jiang Y, Ji X, Ma L, et al
    An immune-related risk gene signature predicts the prognosis of breast cancer.
    Breast Cancer. 2021 Jan 5. pii: 10.1007/s12282-020-01201.
    PubMed     Abstract available


  94. YEN TWF, Garacci Z, Laud PW, Pezzin LE, et al
    Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer.
    Breast Cancer. 2021 Jan 4. pii: 10.1007/s12282-020-01206.
    PubMed     Abstract available


  95. OEI SL, Thronicke A, Matthes H, Schad F, et al
    Assessment of integrative non-pharmacological interventions and quality of life in breast cancer patients using real-world data.
    Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01193.
    PubMed     Abstract available


  96. MIYAKE T, Shimoda M, Tanei T, Kagara N, et al
    Sentinel lymph node biopsy after introducing Twirl(R) breast markers into suspicious lymph nodes in breast cancer patients.
    Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01195.
    PubMed     Abstract available


  97. YAMAGUCHI K, Hara Y, Kitano I, Hamamoto T, et al
    Relationship between MRI findings and invasive breast cancer with podoplanin-positive cancer-associated fibroblasts.
    Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01198.
    PubMed     Abstract available


  98. WANG H, Zhang S, Yee D, Basu S, et al
    Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01194.
    PubMed     Abstract available


  99. CHEN J, Zhang X, Lu Y, Zhang T, et al
    Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01196.
    PubMed     Abstract available


  100. YOKOE T, Kurozumi S, Nozawa K, Ozaki Y, et al
    Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01192.
    PubMed     Abstract available


  101. FUJISAWA F, Kunimasa K, Kano-Fujiwara R, Sato Y, et al
    STK11 loss drives rapid progression in a breast cancer patient resulting in pulmonary tumor thrombotic microangiopathy.
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01200.
    PubMed     Abstract available


  102. OHNUKI K, Tohno E, Tsunoda H, Uematsu T, et al
    Overall assessment system of combined mammography and ultrasound for breast cancer screening in Japan.
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01203.
    PubMed     Abstract available


  103. MICHA AE, Sinnett V, Downey K, Allen S, et al
    Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions.
    Breast Cancer. 2021;28:196-205.
    PubMed     Abstract available


  104. YAGHOUBI S, Gharibi T, Karimi MH, Sadeqi Nezhad M, et al
    Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Breast Cancer. 2021;28:216-225.
    PubMed     Abstract available


  105. WEI Y, Li H, Qu Q
    miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Breast Cancer. 2021;28:175-186.
    PubMed     Abstract available


  106. ZHAO H
    The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Breast Cancer. 2021;28:187-195.
    PubMed     Abstract available


  107. BOLAND MR, Nugent T, Nolan J, O'Mahony J, et al
    Fibromatosis of the breast: a 10-year multi-institutional experience and review of the literature.
    Breast Cancer. 2021;28:168-174.
    PubMed     Abstract available


  108. ZHAO W, Tian Q, Zhao A, Wang B, et al
    The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis.
    Breast Cancer. 2021;28:110-118.
    PubMed     Abstract available


  109. NAHVIJOU A, Safari H, Yousefi M, Rajabi M, et al
    Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
    Breast Cancer. 2021;28:130-136.
    PubMed     Abstract available


  110. SECOMBE KR, Ball IA, Shirren J, Wignall AD, et al
    Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
    Breast Cancer. 2021;28:99-109.
    PubMed     Abstract available


    December 2020
  111. SHAFEI MA, Flemban A, Daly C, Kendrick P, et al
    Differential expression of the BCAT isoforms between breast cancer subtypes.
    Breast Cancer. 2020 Dec 24. pii: 10.1007/s12282-020-01197.
    PubMed     Abstract available


    November 2020
  112. MU G, Ji H, He H, Wang H, et al
    Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients.
    Breast Cancer. 2020 Nov 27. pii: 10.1007/s12282-020-01191.
    PubMed     Abstract available


  113. WANG B, Yan T, Sun L, Zhang G, et al
    A history of severe nausea and vomiting during pregnancy predicts a higher incidence of postoperative nausea and vomiting after breast cancer surgery without breast reconstruction.
    Breast Cancer. 2020 Nov 26. pii: 10.1007/s12282-020-01190.
    PubMed     Abstract available


  114. WU X, Zhang X, Hao Y, Li J, et al
    Obesity-related protein biomarkers for predicting breast cancer risk: an overview of systematic reviews.
    Breast Cancer. 2020 Nov 25. pii: 10.1007/s12282-020-01182.
    PubMed     Abstract available


  115. SAWAKI M, Yamada A, Kumamaru H, Miyata H, et al
    Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.
    Breast Cancer. 2020 Nov 21. pii: 10.1007/s12282-020-01188.
    PubMed     Abstract available


  116. KAWADA K, Taira N, Mizoo T, Suzuki Y, et al
    Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women.
    Breast Cancer. 2020 Nov 13. pii: 10.1007/s12282-020-01185.
    PubMed     Abstract available


  117. NOGUCHI M, Inokuchi M, Noguchi M, Morioka E, et al
    Axillary surgery for breast cancer: past, present, and future.
    Breast Cancer. 2020 Nov 9. pii: 10.1007/s12282-020-01120.
    PubMed     Abstract available


  118. BAN K, Tsunoda H, Togashi S, Kawaguchi Y, et al
    Breast cancer screening using digital breast tomosynthesis compared to digital mammography alone for Japanese women.
    Breast Cancer. 2020 Nov 9. pii: 10.1007/s12282-020-01180.
    PubMed     Abstract available


  119. YU X, Guo J, Zhou Q, Huang W, et al
    A novel immune-related prognostic index for predicting breast cancer overall survival.
    Breast Cancer. 2020 Nov 4. pii: 10.1007/s12282-020-01175.
    PubMed     Abstract available


  120. TANG L, Ma Z, Ishikawa Y, Matsushita H, et al
    Effect of radiotherapy after breast-conserving surgery in elderly patients with early breast cancer according to the AJCC 8th Edition Breast Cancer Staging System in Japan.
    Breast Cancer. 2020 Nov 3. pii: 10.1007/s12282-020-01181.
    PubMed     Abstract available


    October 2020
  121. PRIYADARSHINI R, Raj GM, Sundaram R, Kayal S, et al
    Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjuvant chemotherapy.
    Breast Cancer. 2020 Oct 30. pii: 10.1007/s12282-020-01177.
    PubMed     Abstract available


  122. SAKAMOTO N, Nashimoto M, Nakagawa M, Haruyama Y, et al
    Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer.
    Breast Cancer. 2020 Oct 30. pii: 10.1007/s12282-020-01173.
    PubMed     Abstract available


  123. SHIMA H, Okuno T, Nakamura T, Noro A, et al
    Comparing the extent of breast cancer tumors through contrast-enhanced ultrasound vs B-mode, opposed with pathology: evergreen study.
    Breast Cancer. 2020 Oct 29. pii: 10.1007/s12282-020-01176.
    PubMed     Abstract available


  124. PENG R, Cao J, Guo Q, Sun Q, et al
    Variant in BCAR4 gene correlated with the breast cancer susceptibility and mRNA expression of lncRNA BCAR4 in Chinese Han population.
    Breast Cancer. 2020 Oct 28. pii: 10.1007/s12282-020-01174.
    PubMed     Abstract available


  125. LIAN B, Li H, Liu Y, Chai D, et al
    Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.
    Breast Cancer. 2020 Oct 27. pii: 10.1007/s12282-020-01179.
    PubMed     Abstract available


  126. MASUDA N, Mukai H, Inoue K, Rai Y, et al
    Analysis of subsequent therapy in Japanese patients with hormone receptorpositive/human epidermal growth factor receptor 2negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
    Breast Cancer. 2020 Oct 21. pii: 10.1007/s12282-020-01162.
    PubMed     Abstract available


  127. LIANG H, Zhou G, Lv L, Lu J, et al
    KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
    Breast Cancer. 2020 Oct 16. pii: 10.1007/s12282-020-01170.
    PubMed     Abstract available


  128. LING Y, Cao Q, Liu Y, Zhao J, et al
    Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
    Breast Cancer. 2020 Oct 12. pii: 10.1007/s12282-020-01169.
    PubMed     Abstract available


  129. LAO C, Kuper-Hommel M, Elwood M, Campbell I, et al
    Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
    Breast Cancer. 2020 Oct 12. pii: 10.1007/s12282-020-01171.
    PubMed     Abstract available


  130. HSU YH, Chen VC, Hsieh CC, Weng YP, et al
    Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.
    Breast Cancer. 2020 Oct 8. pii: 10.1007/s12282-020-01168.
    PubMed     Abstract available


    September 2020
  131. BANDEIRA G, Rocha K, Lazar M, Ezquina S, et al
    Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
    Breast Cancer. 2020 Sep 28. pii: 10.1007/s12282-020-01165.
    PubMed     Abstract available


  132. ONISHI N, Kataoka M
    Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies.
    Breast Cancer. 2020 Sep 21. pii: 10.1007/s12282-020-01157.
    PubMed     Abstract available


  133. AHMED M
    Optimizing breast cancer surgery during the COVID-19 pandemic.
    Breast Cancer. 2020 Sep 18. pii: 10.1007/s12282-020-01160.
    PubMed     Abstract available


  134. FUJII T, Ichiba K, Honda C, Tokuda S, et al
    Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients.
    Breast Cancer. 2020 Sep 17. pii: 10.1007/s12282-020-01161.
    PubMed     Abstract available


  135. AHMED M
    Beyond the speed of SOUND.
    Breast Cancer. 2020;27:793-795.
    PubMed     Abstract available


  136. TOMITA M, Oura S, Nishiguchi H, Makimoto S, et al
    A case of bilateral methotrexate-associated diffuse large B-cell lymphomas of the breasts with unique clinical presentation and outcome.
    Breast Cancer. 2020;27:1038-1043.
    PubMed     Abstract available


  137. YAMAGUCHI M, Takagi K, Sato A, Miki Y, et al
    Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.
    Breast Cancer. 2020;27:919-928.
    PubMed     Abstract available


  138. IIDA M, Toyosawa D, Nakamura M, Tsuboi K, et al
    Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
    Breast Cancer. 2020;27:963-972.
    PubMed     Abstract available


  139. JAMIYAN T, Kuroda H, Yamaguchi R, Nakazato Y, et al
    Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
    Breast Cancer. 2020;27:880-892.
    PubMed     Abstract available


  140. CHOI H, Noh H, Cho IJ, Lim ST, et al
    Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
    Breast Cancer. 2020;27:871-879.
    PubMed     Abstract available


  141. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
    Body mass index and gamma-glutamyl transferase expression in normal and cancerous breast tissue.
    Breast Cancer. 2020;27:850-860.
    PubMed     Abstract available


    July 2020
  142. ADACHI Y, Okumura S, Sawaki M, Hattori M, et al
    Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction.
    Breast Cancer. 2020;27:716-723.
    PubMed     Abstract available


  143. CHANG YK, Chen CT, Wang M, Yang Y, et al
    Could ductoscopy alleviate the need of microdochectomy in pathological nipple discharge?
    Breast Cancer. 2020;27:607-612.
    PubMed     Abstract available


  144. ZAHA H, Motonari T, Abe N, Unesoko M, et al
    Fat necrosis in level I oncoplastic breast-conserving surgery focusing on a modified round block technique.
    Breast Cancer. 2020;27:567-572.
    PubMed     Abstract available


    May 2020
  145. REINDERS FCJ, Young-Afat DA, Batenburg MCT, Bruekers SE, et al
    Higher reconstruction failure and less patient-reported satisfaction after post mastectomy radiotherapy with immediate implant-based breast reconstruction compared to immediate autologous breast reconstruction.
    Breast Cancer. 2020;27:435-444.
    PubMed     Abstract available


  146. OKAMOTO S, Chen ST, Covelli JD, DeMartini WB, et al
    High-risk lesions diagnosed at MRI-guided vacuum-assisted breast biopsy: imaging characteristics, outcome of surgical excision or imaging follow-up.
    Breast Cancer. 2020;27:405-414.
    PubMed     Abstract available


  147. VAN EGDOM LSE, de Kock MA, Apon I, Mureau MAM, et al
    Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers.
    Breast Cancer. 2020;27:426-434.
    PubMed     Abstract available


    March 2020
  148. VURAL V, Yilmaz OC
    The Turkish SentiMAG feasibility trial: preliminary results.
    Breast Cancer. 2020;27:261-265.
    PubMed     Abstract available


  149. WADASADAWALA T, Sinha S, Parmar V, Verma S, et al
    Comparison of subjective, objective and patient-reported cosmetic outcomes between accelerated partial breast irradiation and whole breast radiotherapy: a prospective propensity score-matched pair analysis.
    Breast Cancer. 2020;27:206-212.
    PubMed     Abstract available


  150. SOROR T, Lancellotta V, Kovacs G, Lanzotti V, et al
    kOBCS((c)): a novel software calculator program of the Objective Breast Cosmesis Scale (OBCS).
    Breast Cancer. 2020;27:179-185.
    PubMed     Abstract available


    January 2020
  151. IZUMORI A, Kokubu Y, Sato K, Gomi N, et al
    Usefulness of second-look ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities.
    Breast Cancer. 2020;27:129-139.
    PubMed     Abstract available


  152. YOU C, Zhang Y, Gu Y, Xiao Q, et al
    Comparison of the diagnostic performance of synthesized two-dimensional mammography and full-field digital mammography alone or in combination with digital breast tomosynthesis.
    Breast Cancer. 2020;27:47-53.
    PubMed     Abstract available


  153. NAGURA N, Hayashi N, Takei J, Yoshida A, et al
    Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    Breast Cancer. 2020;27:70-76.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: